A Systematic Literature Review (SLR) of Health State Utility Values (HSUV) in Metastatic Castration-Resistant Prostate Cancer (MCRPC)


Castro E1, Debnath A2, Olsen C2, Craigie S2, Nazari J3, Niyazov A3, Samjoo I2
1Hospital Universitario 12 de Octubre, Madrid, Spain, 2EVERSANA, Burlington, ON, Canada, 3Pfizer Inc., New York, NY, USA

OBJECTIVES: The treatment landscape for mCRPC has broadened since the introduction of taxane-based chemotherapies. The aim of this study was to systematically identify and summarize HSUVs among men with mCRPC.

METHODS: An SLR was conducted to identify HSUVs in first-line (1L) asymptomatic or mildly symptomatic adult men with mCRPC. MEDLINE®, Embase, and Cochrane CENTRAL were searched from inception to October 2022 using Ovid®. Supplemental searches of key conferences (2019 to 2022), health technology assessment (HTA) agencies, regulatory bodies, ClinicalTrials.gov, ScHARRHUD Health Utilities Database, Tufts CEA Registry, and HERC Database of Mapping Studies were also conducted (PROSPERO registration: CRD42021283512).

RESULTS: Fifteen publications (8 primary utility studies, 3 economic evaluations, 3 HTA documents, and 1 therapeutic review) were identified that reported HSUVs in 1L and later-line mCRPC. Therapies included novel hormone therapy, chemotherapy (docetaxel, cabazitaxel, mitoxantrone, estramustine), anti-androgen therapy (bicalutamide), and immunotherapy (sipuleucel-T). HSUVs for the following health states were identified: baseline (0.7 to 0.9; n = 10), stable disease/during 1L therapy (0.538 to 0.9; n = 10), progression on 1L therapy (0.58 to 0.70; n = 7), during second-line (2L) therapy (0.66 to 0.83; n = 3), progression on 2L therapy (0.6 to 0.66; n = 3), and palliative care (0.5; n = 3).

CONCLUSIONS: HSUVs trended towards lower values with progressing lines of therapy. As novel treatments for mCRPC have emerged in the past decade, this study provides a comprehensive synthesis of current HSUV evidence in adults with mCRPC receiving 1L and later-line therapy. Limitations include hampered comparability between studies due to heterogeneity in study designs (e.g., measuring, quantifying, and reporting HSUVs) and treatments assessed. Future reviews with broader inclusion criteria that examine HSUVs in mCRPC patients receiving later-line therapy are warranted to understand patient quality of life in the context of novel treatments.

Conference/Value in Health Info

2023-05, ISPOR 2023, Boston, MA, USA

Value in Health, Volume 26, Issue 6, S2 (June 2023)




Patient-Centered Research, Study Approaches

Topic Subcategory

Health State Utilities, Literature Review & Synthesis


No Additional Disease & Conditions/Specialized Treatment Areas

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now